Immunity, autoimmunity and inflammatory bowel disease

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 1-2

  Cassinotti, Andrea ^a   Sarzi Puttini, Piercarlo ^a   Fichera, Maria ^a   Shoenfeld, Yoehuda ^b   de Franchis, Roberto ^a   Ardizzone, Sandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

AUTOIMMUNITY; CROHN DISEASE; EDITORIAL; ENTERITIS; IMMUNITY; IMMUNOGENICITY; PATHOGENESIS; ULCERATIVE COLITIS;

ANIMALS; AUTOIMMUNITY; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84886948570     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.007     Document Type: Editorial

References (18)

1. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
2. Ordàs I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet 2012, 380:1606-1619.
3. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997, 273:G769-G775.
4. Danese S., Sans M., Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004, 3:394-400.
5. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2013, [pii: S1568-9972(13)00104-3].
6. Monteleone G., Caruso R., Pallone F. Targets for new immunomodulation strategies in IBD. Autoimmun Rev 2013, [pii: S1568-9972(13)00103-1]. 10.1016/j.autrev.2013.06.003.
7. Ardizzone S., Puttini P.S., Cassinotti A., Bianchi-Porro G. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008, 40(Suppl. 2):S253-S259.
8. Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev 2013, [pii: S1568-9972(13)00105-5]. 10.1016/j.autrev.2013.06.005.
9. Cassinotti A., Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009, 15:1264-1275.
10. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2013, 13:24-30.
11. Atzeni F., Talotta R., Benucci M., Salaffi F., Cassinotti A., Varisco V., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12(7):703-708.
12. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
13. Hanauer S., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-543.
14. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
15. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
16. Seow C.H., Newman A., Irwin S.P., Steinhart A.H., Silverberg M.S., Greenberg G.R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 2010, 59:49-54.
17. Cassinotti A., Travis S. Why don't we just measure infliximab drug levels in IBD?. Pract Gastroenterol 2010, 34:11-20.
18. Afif W., Loftus E.V., Faubion W., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.